文献速递肝病

IL-6/STAT3轴决定PNPLA3介导的非酒精性脂肪性肝病易感性

IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
PubMed 文献 · J Hepatol · 2022-08-30

研究利用人多能干细胞来源的肝细胞、肝星状细胞和巨噬细胞构建多细胞肝脏培养体系,在脂毒性环境下比较rs738409位点同基因配对培养物的NAFLD表型。携带I148M变异的培养物NAFLD表型加重,伴IL-6/STAT3活性升高;抑制IL-6/STAT3可减轻该易感性,而增强则加重野生型培养物的NAFLD发展。

要点

  • I148M变异在脂毒性条件下导致NAFLD表型增强发展。
  • 该差异与肝脏培养物中IL-6/STAT3活性升高相关,与携带rs738409 SNP个体肝活检转录组数据一致。
  • 抑制IL-6/STAT3可减轻I148M介导的NAFLD易感性,增强则加重野生型培养物的NAFLD发展。

核心结论

  • 研究揭示IL-6/STAT3活性升高与148M介导的NAFLD易感性之间存在潜在因果联系。
  • 该人多能干细胞来源多细胞肝脏培养体系是探索NAFLD遗传变异的可用平台。

研究设计与样本

  • 研究构建了整合人多能干细胞来源肝细胞、肝星状细胞和巨噬细胞的多细胞肝脏培养体系。
  • 利用反映患者循环风险因子水平的脂毒性环境建模NAFLD,并创建仅rs738409位点不同的同基因配对肝脏培养物进行比较。

主要发现

  • 多细胞肝脏培养物重现了NAFLD发生和进展的多个关键特征,包括脂质蓄积和氧化应激、炎症反应及星状细胞活化。
  • 脂毒性条件下,I148M变异导致NAFLD表型增强发展。
  • 这些差异与肝脏培养物中IL-6/信号转导及转录激活因子3(STAT3)活性升高相关,与携带rs738409 SNP个体肝活检转录组数据一致。
  • 抑制IL-6/STAT3活性减轻I148M介导的NAFLD易感性,而在野生型肝脏培养物中增强该活性则加重NAFLD发展。
  • 携带rs738409 SNP的肝脏培养物中IL-6/STAT3活性升高被归因于NF-κB活性增加。

关键数值与推荐

  • 研究聚焦于rs738409 C>G单核苷酸多态性(SNP),该变异产生PNPLA3的I148M变体并与NAFLD强相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A number of genetic polymorphisms have been associated with susceptibility to or protection against non-alcoholic fatty liver disease (NAFLD), but the underlying mechanisms remain unknown. Here, we focused on the rs738409 C>G single nucleotide polymorphism (SNP), which produces the I148M variant of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and is strongly associated with NAFLD. METHODS: To enable mechanistic dissection, we developed a human pluripotent stem cell (hPSC)-derived multicellular liver culture by incorporating hPSC-derived hepatocytes, hepatic stellate cells, and macrophages. We first applied this liver culture to model NAFLD by utilising a lipotoxic milieu reflecting the circulating levels of disease risk factors in affected individuals. We then created an isogenic pair of liver cultures differing only at rs738049 and compared NAFLD phenotype development. RESULTS: Our hPSC-derived liver culture recapitulated many key characteristics of NAFLD development and progression including lipid accumulation and oxidative stress, inflammatory response, and stellate cell activation. Under the lipotoxic conditions, the I148M variant caused the enhanced development of NAFLD phenotypes. These differences were associated with elevated IL-6/signal transducer and activator of transcription 3 (STAT3) activity in liver cultures, consistent with transcriptomic data of liver biopsies from individuals carrying the rs738409 SNP. Dampening IL-6/STAT3 activity alleviated the I148M-mediated susceptibility to NAFLD, whereas boosting it in wild-type liver cultures enhanced NAFLD development. Finally, we attributed this elevated IL-6/STAT3 activity in liver cultures carrying the rs738409 SNP to increased NF-κB activity. CONCLUSIONS: Our study thus reveals a potential causal link between elevated IL-6/STAT3 activity and 148M-mediated susceptibility to NAFLD. IMPACT AND IMPLICATIONS: An increasing number of genetic variants manifest in non-alcoholic fatty liver disease (NAFLD) development and progression; however, the underlying mechanisms remain elusive. To study these variants in human-relevant systems, we developed an induced pluripotent stem cell-derived multicellular liver culture and focused on a common genetic variant (i.e. rs738409 in PNPLA3). Our findings not only provide mechanistic insight, but also a potential therapeutic strategy for NAFLD driven by this genetic variant in PNPLA3. Our liver culture is therefore a useful platform for exploring genetic variants in NAFLD development.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J Hepatol. 2022. PMID: 36049612. doi:10.1016/j.jhep.2022.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。